Impact of pre-transplant time on dialysis on survival in patients with lupus nephritis

Eleana Ntatsaki1,2 · Alba Velo-Garcia1,3 · Vassilios S. Vassiliou4,5 · Alan D. Salama6 · David A. Isenberg1

Received: 18 January 2018 / Revised: 2 April 2018 / Accepted: 17 April 2018 / Published online: 11 May 2018 © The Author(s) 2018

Abstract
Lupus nephritis (LN) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE) often leading to end-stage renal failure (ESRF) and necessitating renal transplantation (rTp). Optimal timing of rTp in SLE patients with ESRF is uncertain and could potentially affect survival. We investigated the time spent on dialysis before rTp and survival following rTp in a cohort of SLE patients. Retrospective analysis of all adult SLE patients receiving rTp over a 40-year period (1975–2015) in two tertiary UK centres. Cox proportional hazard regression and receiver operator curves (ROC) were used to determine the risk associated with time on dialysis before rTp and other potential predictors. Forty patients (age 35 ± 11 years, 34 female, 15 Caucasian, 15 Afro–Caribbean and 10 South Asian) underwent rTp. During a median follow-up of 104 months (IQR 80,145), eight (20%) patients died and the 5-year survival was 95%. Univariate analysis identified time on dialysis prior to rTp as the only potentially modifiable risk predictor of survival with a hazard ratio of 1.013 for each additional month spent on dialysis (95% CI = 1.001–1.026, p = 0.03). ROC curves demonstrated that > 24 months on dialysis had an adverse effect with sensitivity of 0.875 and specificity 0.500 for death. No other modifiable predictors were significantly associated with mortality, indicating that time on dialysis had an independent effect. Increased time on dialysis pre-transplantation is an independent modifiable risk factor of mortality in this cohort of patients with lupus nephritis.

Keywords Lupus nephritis · Outcome · Renal transplant · SLE · Survival

Introduction
Systemic lupus erythematosus (SLE) is a heterogenous autoimmune rheumatic disease with particularly high prevalence in women of childbearing age [1]. The kidneys are often affected, with at least one-third of SLE patients developing overt renal disease, while 10–25% may reach end-stage renal failure (ESRF) requiring dialysis or kidney transplantation and 10–20% of patients die within 10 years [2]. Lupus nephritis (LN) remains one of the most common and severe manifestations of SLE. There are racial, ethnic and regional variations in the incidence, prevalence and prognosis of LN [3]. Specifically younger age (< 33 years), non-European ancestry and male gender (in some but not all series) were found to associate with earlier development of renal disease. Moreover, African–Caribbean, African–American and South Asian ethnicities usually have worse renal involvement when compared to other ethnic groups. Furthermore, Black and Hispanic patients with LN tend to have poorer prognosis and a higher risk of renal disease and mortality [4].

In those patients reaching ESRF, renal transplantation (rTp) has now become an accepted and preferred treatment. However, in the early era of renal transplantation, lupus patients were considered unfavourable candidates given an assumed risk of recurrent LN. Since 1975, however, when it was first suggested that the outcomes of transplant in SLE are comparable to non-SLE patients [5], there have been reports...
across the globe and in different ethnic populations that have shown low recurrence rates of LN in kidney transplant recipients [6–9]. Some studies, however, have raised concern regarding worse graft and patient survival of SLE patients when compared to other patient groups (e.g. patients with diabetes), with unfavourable comparative outcomes, especially for the recipients of deceased donors [10]. Nonetheless, there is a relative paucity of data in the literature regarding long-term outcomes of patients with LN and renal transplantation. Specifically, although in other patient cohorts undergoing renal transplantation the time spent on dialysis prior to the transplantation has been studied, showing that the longer a patient spends on dialysis, the worse the overall survival after the transplantation [11–13], this has not been specifically investigated for lupus patients. As time spent on dialysis before the transplantation can be a potentially modifiable factor, it is important to identify whether this is indeed a risk predictor in the lupus patients and whether there is a “safe maximum” time on dialysis before transplantation. We therefore investigated the long-term survival of patients with LN receiving rTp and the prognostic effect of the time spent on dialysis pre-transplant in our cohort of LN patients from two major London hospitals followed up since 1975.

Methods

This was a retrospective review of all adult SLE patients (aged > 18 years) from two major London, UK institutions: University College London Hospital (UCLH) and Royal Free Hospital (RFH), who developed renal failure and received a renal transplant over a 40-year period (1975–2015). Hospital notes, electronic records and correspondence from family physicians and physicians in other hospitals were reviewed. All patients with SLE and related end-stage renal failure (defined as the need of chronic dialysis therapy or kidney transplantation due to primarily lupus nephritis) and who required renal transplantation from January 1975 to December 2015 were included in this study. In all patients, 6 months of disease quiescence was required prior to transplantation to be included. All patients fulfilled four or more of the 1982 revised classification criteria for SLE of the American College of Rheumatology [14] and histological class of lupus nephritis was defined according to the International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification system [15], applied retrospectively for the patients who had undergone transplantation prior to 2003.

Published modifiable and non-modifiable parameters possibly associating with survival were considered, as shown in Table 1, and recorded for this cohort. This study was a retrospective review of a long-term observational registry for which University College London does not require formal ethical permission.

The primary endpoint was patient death. Mortality was assessed from dedicated SLE-transplant clinics and also from the database at the Office on National Statistics, a dedicated national registry where all the deaths in UK are recorded.

Statistical analysis

Continuous variables are presented as mean and standard deviation. Categorical variables are presented as numbers and percentages. Cox proportional hazard regression and receiver operating characteristic (ROC) curves are used to determine potential predictors. The cumulative survival curves are drawn using the Kaplan–Meier method. Patient characteristics are summarised and expressed as mean ± SD (if normally distributed) or otherwise median and interquartile range (IQR). Comparison between living and dead patients was undertaken using chi-square, t test and Mann-Whitney non-parametric t test. A p < 0.05 was considered significant. IBM SPSS version 22 (IBM Corp., Armonk, NY, USA) was used for statistical analysis.

Results

A total of 361 patients with lupus nephritis were identified (155 from RFH and 206 from UCLH). During the 42-year period of follow-up, 121 progressed to ESRF and 40 of these patients received a renal transplant (eight patients had been seen in both hospitals and included in the
hospital where they were first seen). The patient characteristics and demographics are presented in Table 2.

Mean age at transplantation was 36 ± 11 years, and 34 (85%) were female. The self-reported ethnic distribution was similar to that seen in the general lupus cohort of the two hospitals, with 15 Caucasian (37.5%), 15 Afro-Caribbean (37.5%), and 10 South Asian (25.0%) undergoing rTp. Five patients were re-transplanted (two patients received a total of two transplants, and one patient received a total of three transplants). Follow-up time was initiated after the first transplant. Two of our patients (5%) had pre-emptive transplantation and the dialysis time for them was included as zero.

During a median follow-up of 104 months (IQR 80,145) 8 (20%), patients died (Table 3) and the 5-year survival was 95% which appeared similar across all decades (Table 4).

Three patients (37.5%) died as a consequence of sepsis, two as a consequence of uraemic complications (25%), two secondary to malignancy (25%) and one secondary to ischaemic heart disease (12.5%). Using univariate Cox regression time on dialysis and the other potential predictors of survival were investigated. Univariate analysis only identified time on dialysis prior to rTp as a predictor of survival with a hazard ratio of 1.013 for each additional month spent on dialysis (95% CI = 1.001–1.026, \( p = 0.03 \)). No other parameter reached statistical significance as shown in Table 5. In particular, gender \(( p = 0.44 \)), ethnicity \(( p = 0.99 \)), age at SLE diagnosis \(( p = 0.55 \)), age at LN \(( p = 0.94 \)), age at rTp \(( p = 0.43 \)), time between SLE diagnosis and LN \(( p = 0.37 \)), time between LN and dialysis \(( p = 0.54 \)) or indeed any other clinical co-existing diagnosis; DM \(( p = 0.56 \)), hypertension \(( p = 0.32 \)), dyslipidaemia \(( p = 0.91 \)) did not affect survival. There was no difference between the decade the transplant took place and the outcome \(( p = 0.71 \)) but this should be interpreted with caution in view of the low number of rTp undertaken in the earlier decades. We also compared the length of time on dialysis prior to transplantation in the patients who received the transplant before or after 2000, which was not statistically different \(( p = 0.181 \)). Therefore, these results suggest that the time on dialysis was the only independent modifiable risk factor associated with mortality, irrespective of the decade the transplantation took place.

Nine patients had received mycophenolate mofetil (MMF)/tacrolimus combination only, with no previous AZA or cyclosporine use, with the other patients having used (azathioprine) AZA or cyclosporine at any stage. The nine patients who

---

### Table 2

Demographic, clinical and histological features of the patients. SLE systemic lupus erythematosus, rTp renal transplantation, ESRF end-stage renal failure, LN lupus nephritis

| Demographic characteristics | Patient (n = 40) |
|----------------------------|----------------|
| Gender/female              | 34             |
| Ethnicity                  |                |
| Caucasian                  | 15             |
| Black                      | 15             |
| Asian                      | 10             |
| Age at SLE diagnosis       | 21.1 ± 9.2     |
| Age at ESRF                | 31.6 ± 10.4    |
| Age at rTp                 | 35.5 ± 11.0    |
| Time on dialysis (months)  | 43 (13–49)     |
| Time of follow-up (months) | 104 (80–145)   |
| Type IV LN                 | 18             |
| Donor source/cadaveric     | 22             |
| Graft failure              | 9              |

### Table 3

Comparison of clinical demographics between patients who survived and who died after the renal transplantation

|                          | Alive (n = 32) | Dead (n = 8) | \( p \) value |
|--------------------------|---------------|-------------|--------------|
| Gender/female            | 26            | 8           | 0.32         |
| Age at lupus diagnosis (years) | 21 ± 10   | 22 ± 9     | 0.77         |
| Age LN                   | 26 ± 8        | 26 ± 9      | 0.97         |
| Age at ESRF              | 31 ± 9        | 33 ± 15     | 0.73         |
| Age at renal transplantation (years) | 36 ± 11  | 39 ± 14    | 0.34         |
| Duration on dialysis prior to renal transplantations (months) | 31 (12–39) | 84 (68–90) | 0.01         |
| Ethnicity                |               |             |              |
| Caucasian                | 11 (34%)      | 4 (50%)     | 0.94         |
| Black                    | 15 (47%)      | 0           |              |
| Asian                    | 6 (19%)       | 4 (50%)     |              |
| Type of dialysis, HD/PD* | 17/9          | 3/3         | 0.64         |

*Eight patients required both PD and HD and therefore not included in the direct comparison between PD and HD. However, even when compared with PD or HD, there was no evidence that those who required both types of dialysis have worse outcome \(( p = 0.89 \))

LN lupus nephritis, ESRF end-stage renal failure, HD haemodialysis, PD peritoneal dialysis
received MMF/tacrolimus only had an overall mortality of 11.1% compared to the patients who ever received AZA/cyclosporine who had a mortality of 22.5%, although this difference did not reach statistical significance ($p = 0.45$).

Finally, there was also no difference between the type of dialysis undertaken pre-transplantation and whether it was haemodialysis or peritoneal dialysis ($p = 0.64$).

Utilising specifically the time spent on dialysis before the transplantation, a ROC curve was used to calculate the optimal maximum time spent on dialysis prior to conferring an adverse outcome (Fig. 1) showing that > 24 months on dialysis had an adverse effect on survival, with an area under the ROC curve of 0.795, sensitivity of 0.875 and specificity 0.500 for death.

Utilising this dichotomous value, there was a 2.8-fold higher risk of mortality in those patients who spent longer than 24 months on dialysis using Kaplan–Meier curves (Fig. 2), although there was only a trend towards statistical significance seen (log rank $p = 0.15$). This supports the results from the Cox regression which showed that mortality was increased by 1.3% for every additional month on dialysis (or 15.6% for every additional year on dialysis) and that most likely if transplantation could be undertaken by 24 months on dialysis, or even earlier, it could be of benefit to the patients.

Although not the aim of our study, we also compared the overall survival of the patients with LN-related ESRF receiving transplantation vs the ones without transplantation. In total, 45/81 (56%) died in the non-transplanted patients compared with 8/40 (20%) of those who received at least one renal transplant ($p = 0.0002$). Although the superiority of renal transplantation in this context is well recognised [16], this result could have been confounded by higher burden of comorbidity in the patients not selected for transplantation.

| Table 4 | Comparison of 5-year mortality according to the decade the transplant was received |
|---------|---------------------------------------------------------------------|
| Dialysis per decade— | Patients | Mortality |
| || per decade | 5-year survival |
| 1975–85 | 2 | 0/2 | 0.97 |
| 1985–95 | 3 | 1/3 (33%) | |
| 1995–05 | 8 | 2/8 (40%) | |
| 2005–15 | 27 | 0/24 | |

*Three patients from the 2005–2015 decade are alive but have not completed 5 years out from the transplantation and hence are not included in the table, explaining why it is 0/24 in the last decade.

Table 5 Univariate Cox proportional hazard modelling investigating the association of various parameters and mortality showing that only risk factor associated with prognosis was time on dialysis, with longer time on dialysis associated with worse prognosis. SLE systemic lupus erythematosus, LN lupus nephritis, ESRF end-stage renal failure, rTp renal transplantation, PD peritoneal dialysis, HD haemodialysis, APLS antiphospholipid syndrome, MI myocardial infarction, TIA transient ischaemic attack

| Factor | $p$ value | HR | 95% CI |
|--------|----------|----|--------|
| Time on dialysis/per month | 0.031 | 1.013 | 1.001–1.026 |
| Gender/male | 0.442 | 0.038 | 0.001–161.3 |
| Ethnicity | 0.987 | 0.995 | 0.537–1.844 |
| Age at SLE diagnosis | 0.552 | 1.021 | 0.953–1.094 |
| Age of LN | 0.941 | 1.003 | 0.920–1.092 |
| Age of ESRF | 0.836 | 1.008 | 0.935–1.087 |
| Age at rTp | 0.431 | 1.026 | 0.963–1.092 |
| Dialysis PD (vs HD) | 0.764 | 0.706 | 0.073–6.862 |
| Time between SLE and LN | 0.373 | 0.996 | 0.987–1.005 |
| Time between LN and dialysis | 0.540 | 0.999 | 0.994–1.003 |
| LN duration before dialysis | 0.152 | 1.066 | 0.977–1.164 |
| Type IV LN | 0.398 | 2.533 | 0.294–21.82 |
| Dialysis decade | 0.712 | 0.872 | 0.420–1.807 |
| Diabetes mellitus | 0.561 | 0.038 | 0.001–2319 |
| Hypertension | 0.323 | 0.329 | 0.360–2.987 |
| Dyslipidaemia | 0.905 | 0.872 | 0.092–8.234 |
| APLS | 0.508 | 0.036 | 0.000–672.6 |
| Cardiac disease (MI, stroke, TIA) | 0.873 | 1.071 | 0.463–2.476 |
| Donor source (living) | 0.353 | 0.459 | 0.089–2.372 |
| Graft failure post rTp | 0.314 | 2.073 | 0.501–8.567 |
Discussion

Patients with lupus nephritis represent a complex cohort of patients which should be managed optimally to ensure longer-term survival. In the present study, we focused on time spent on dialysis pre-transplantation for renal nephritis as a potentially modifiable predictor of patient mortality, rather than predictor of graft failure. We also investigated other potential predictors of survival both modifiable and non-modifiable. We included patients going back to the early times of rTp in LN from 1975 and we present data on the longest reported follow-up period for a dedicated cohort of patients with LN undergoing renal transplantation. We identified a 5-year survival of 95% which is in line or better than other published studies [9, 10, 17]. Survival did not appear to differ in relation to the decade the rTp took place, although this should be considered within the context of the low numbers of rTp in the very early decades meaning that the study might have been underpowered to detect a small but clinically important difference.

The only variable that appeared to offer any prognostic association with mortality was time spent on dialysis prior to the transplant. For every additional month on dialysis, prognosis worsened by 1.3%. If patients exceeded a binary cut-off of 24 months on dialysis in our cohort, there was a suggestion that this conferred almost a threefold increase in mortality. No other factors appeared to affect mortality, as they did not reach significance in univariate analysis.

The optimal timing of transplantation in patients with LN reaching ESRF is not known, but this study would support earlier transplantation if feasible. This is similar to recent work which found that increased time on dialysis led to increased graft failure [9, 18]. Indeed, our cohort included two patients with pre-emptive transplantation and they both remain alive at 22 and 12 years respectively, supporting that the earlier benefits of rTp. Although our research identifies the cut-off of 24 months which could be used to prioritise rTp in LN patients, further larger and prospective studies are necessary to identify whether the time relationship to survival up to 24 months is a linear one or whether an even much earlier and possibly even pre-emptive transplantation should be recommended and incorporated in current guidelines.

Limitations

Despite combining the data from two large institutions, we only had 40 patients to analyse, which is however in line or larger than other similar published studies [9, 17]. Our cohort also included a mixture of Caucasian, Afro–Caribbean and South Asian patients and we cannot necessarily extrapolate our results to patients from other ethnicities. Larger studies including multiple ethnicities will also allow further comparisons. Finally, despite a very long follow-up of 422 patient-years, only eight patients reached the study endpoint which may have reduced the identification of the impact of other potentially predictive variables, for example sex and presence of antiphospholipid syndrome in particular, which had a wide confidence interval in our results. In addition, although we could only undertake univariate analysis due to the small number of outcomes, this still allows us to accurately identify individual predictors and trends towards mortality. Especially as only the time on dialysis was significant, with patients spending similar times on dialysis throughout the 40-
year period, we can be confident that this was not influenced or affected by other parameters. Nonetheless, we propose that ultimately, multicentre interventional studies are required to provide adequate power to address this specific question.

Conclusion

In conclusion, in this long-term follow-up study of patients with SLE and rTP from two large institutions spanning across four decades, we identified that the only potential modifiable factor to improve survival was reducing the time on dialysis prior to transplantation. This finding should be validated in larger multicentre studies and help identify the optimal timing of transplantation in LN following ESRF whether on dialysis or pre-emptively [19].

Source of funding This work was supported by LUPUS UK.

Author’s contributions EN study planning, obtaining funding, data collection, drafting manuscript
AVG data collection, significant revisions to manuscript
VSV statistical analysis, significant revisions to manuscript
ADS study planning, obtaining funding, data collection, significant revisions to manuscript DAI study planning, obtaining funding, data collection, significant revisions to manuscript

Compliance with ethical standards

This study was a retrospective review of a long-term observational registry for which University College London does not require formal ethical permission.

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the license, and indicate if changes were made.

References

1. Lisnevskaia L, Murphy G, Isenberg D (2014) Systemic lupus erythematosus. Lancet 384:1878–1888. https://doi.org/10.1016/S0140-6736(14)00128-8
2. Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358:929–939. https://doi.org/10.1056/NEJMra071297
3. Adler M, Chambers S, Edwards C, Neil G, Isenberg D (2006) An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford) 45: 1144–1147. https://doi.org/10.1093/rheumatology/kek039
4. Natsaki E, Isenberg D (2015) Risk factors for renal disease in systemic lupus erythematosus and their clinical implications. Expert Rev Clin Immunol 11:837–848. https://doi.org/10.1586/1744666X.2015.1045418
5. Barnes B, Bergan J, Braun W et al (1975) Renal transplantation in congenital and metabolic diseases. A report from the ASC/NIH renal transplant registry. JAMA 232:148–153
6. Yu TM, Chen YH, Lan JL, Cheng CH, Chen CH, Wu MJ, Shu KH (2008) Renal outcome and evolution of disease activity in Chinese lupus patients after renal transplantation. Lupus 17:687–694. https://doi.org/10.1177/0961203308089349
7. Oliveira CS, d Oliveira I, Bacchigia AABS, et al (2012) Renal transplantation in lupus nephritis: a Brazilian cohort. Lupus 21:570–574. doi: https://doi.org/10.1177/0961203311430220
8. Houssiau FA, Vasconcelos C, D’Cruz D et al (2010) The 10-year follow-up data of the Euro–Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69:61–64. https://doi.org/10.1136/ard.2008.102533
9. Cairoli E, Sanchez-Marcos C, Espinosa G, Glucksmann C, Ercilla G, Oppenheimer F, Cervera R (2014) Renal transplantation in systemic lupus erythematosus: outcome and prognostic factors in 50 cases from a single centre. Biomed Res Int 2014:746192–746197. https://doi.org/10.1155/2014/746192
10. Chelamcharla M, Javaid B, Baird BC, Goldfarb-Rumyantzev AS (2007) The outcome of renal transplantation among systemic lupus erythematosus patients. Nephrol Dial Transplant 22:3623–3630. https://doi.org/10.1093/ndt/gfm459
11. Cosio FG, Alamir A, Yim S, Pesavento TE, Falkenhain ME, Henry AG, Henry VSV statistical analysis, significant revisions to manuscript
12. Resende L, Guerra J, Santana A, Mil-Homens C, Abreu F, da Costa ML, Elkhammas EA, Davies EA, Bumgardner GL, Ferguson RM (1998) Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. Kidney Int 53:767–772. https://doi.org/10.1046/j.1523-1755.1998.00787.x
13. West JC, Bisordi JE, Squiers EC et al (1992) Length of time on dialysis prior to renal transplantation is a critical factor affecting patient survival after allografting. Transpl Int 5(Suppl 1):S148–S150
14. Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
15. Weening JJ, D’Agati VD, Schwartz MM et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65:521–530. https://doi.org/10.1111/j.1523-1755.2004.00443.x
16. Sabucedo AJ, Contreras G (2015) ESKD, transplantation, and dialysis in lupus nephritis. Semin Nephrol 35:500–508. https://doi.org/10.1053/j.semnephrol.2015.08.011
17. Lionaki S, Kapitsinou PP, Iniotaki A, Kostakis A, Moutsopoulos HM, Boletis JN (2008) Kidney transplantation in lupus patients: a case-control study from a single centre. Lupus 17:670–675. https://doi.org/10.1177/096120330889430
18. Plantinga LC, Patzer RE, Drenkard C, Kramer MR, Klein M, Lim SS, McClellan WM, Pastan SO (2015) Association of time to kidney transplantation with graft failure among U.S. patients with end-stage renal disease due to lupus nephritis. Arthritis Care Res (Hoboken) 67:571–581. https://doi.org/10.1002/acr.22482
19. Naveed A et al (2011) Preemptive kidney transplantation in systemic lupus erythematosus. Transplant Proc 43:3713–3714. https://doi.org/10.1016/j.transproceed.2011.08.092